Immutep (IMMP) announces positive initial efficacy data and favorable safety data for IMP761
From Yahoo Finance: 2025-06-29 13:28:00
Immutep Limited (NASDAQ: IMMP) announced positive initial efficacy data and continued favorable safety data for its first-in-class LAG-3 agonist antibody, IMP761. The company reported no treatment-associated adverse events in healthy participants at the highest dosing level of 0.9 mg/kg.
Immutep (IMMP) is progressing with single ascending dose levels of 2.5, 7, and 14 mg/kg for IMP761, targeting autoimmune diseases like rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis. The company believes IMP761 is the first LAG-3 agonist antibody that could potentially treat these large market disorders.
IMP761 aims to restore balance to the immune system by enhancing the “brake” function of LAG-3, silencing dysregulated self-antigen-specific memory T cells. Immutep Limited (NASDAQ: IMMP) is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases.
While Immutep (IMMP) shows growth potential, other AI stocks may offer greater returns with limited downside risk. For a promising AI stock with 100x upside potential, consider exploring the report on the cheapest AI stock. Disclosure: None.
Read more: Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data